Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) rose 5.4% during trading on Wednesday . The company traded as high as $9.48 and last traded at $9.21. Approximately 623,250 shares changed hands during trading, an increase of 32% from the average daily volume of 473,757 shares. The stock had previously closed at $8.74.
ADAP has been the subject of a number of recent research reports. BidaskClub downgraded Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, December 20th. ValuEngine downgraded Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $11.58.
The company has a market capitalization of $862.85 and a price-to-earnings ratio of -12.28.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Raymond James & Associates purchased a new stake in shares of Adaptimmune Therapeutics in the fourth quarter valued at $114,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Adaptimmune Therapeutics in the third quarter valued at $182,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Adaptimmune Therapeutics in the third quarter valued at $199,000. Iguana Healthcare Management LLC purchased a new stake in shares of Adaptimmune Therapeutics in the third quarter valued at $205,000. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of Adaptimmune Therapeutics in the fourth quarter valued at $244,000. Institutional investors own 55.58% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Adaptimmune Therapeutics (ADAP) Stock Price Up 5.4%” was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.thelincolnianonline.com/2018/03/14/adaptimmune-therapeutics-adap-stock-price-up-5-4.html.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.